BSX's Alair Receives Reimbursement - Analyst Blog
January 05 2012 - 6:45AM
Zacks
Boston Scientific
Corporation (BSX) received a major breakthrough for its
Alair Bronchial Thermoplasty (“BT”) system with the Centers for
Medicare and Medicaid Services ("CMS") acknowledging the benefit of
the treatment.
As a result, effective January 1,
2012, Medicare will be reimbursing the Alair catheter through a
"pass-through" payment when the procedure is performed in an
outpatient hospital setting, in addition to reimbursing the
bronchial thermoplasty procedure. This should therefore encourage
private insurers to provide reimbursement for bronchial
thermoplasty.
The reimbursement decision from
Medicare does not surprise us since the company had previously
presented positive results of the treatment procedure. Data from
the Research in Severe Asthma (“RISA”) trial found that patients
with severe refractory asthma, when treated with Alair BT system,
experienced stability in lung function without clinical
complications over a five-year period.
Long-term safety data from the RISA
trial also concurred with another five-year data from the Asthma
Intervention Research (“AIR”) study. The AIR trial comparing BT
with the standard of care, for patients with moderate-to-severe
asthma, also condoned the long-term safety profile of the BT
system.
Moreover, findings from the Asthma
Intervention Research 2 (“AIR2”) trial showed persistence of safety
and effectiveness of BT after two years. Besides, results from AIR2
trial after one year also demonstrated positive outcome with
respect to reduction in asthma attacks (by 32%), emergency room
visits for respiratory symptoms (84%) and days lost from work
(66%).
Alair was inducted in Boston
Scientific’s portfolio with its acquisition of Asthmatx in October
2010. The Alair BT system provides long lasting and improved asthma
control for adult patients suffering from severe asthma who have
not benefited from current inhaled medications.
Alair has been approved in both
Europe and the US and is the first device-based asthma treatment
approved by the US Food and Drug Administration (FDA). Alair has
been available in the UK since June 2011 and in other European
countries since September 2011.
Asthma is one of the most common
ailments in the world that involves a costly treatment process and
afflicts more than 20 million Americans. Besides, the prevalence of
asthma has grown in recent decades without any cure.
Approximately 5% of Americans suffering from asthma are diagnosed
with severe persistent asthma.
Our Take
We believe that favorable decision
from CMS should lead to better acceptance of Alair going ahead. The
company is banking on the product to strengthen its offering of
pulmonary devices and should contribute to growth and
diversification of the Endoscopy business in future. The stock
carries a Zacks #2 Rank (“Buy”) in the short term.
However, the current scenario is
challenging for MedTech companies when the core segments of stents
and defibrillators are struggling for growth due to pricing
pressure and a loss of market share. Boston Scientific is not alone
and its peers Medtronic (MDT) and St Jude
Medical (STJ) are also witnessing similar challenges. In
this scenario, the company is working on reviving its top line by
expanding its product portfolio, either through pipeline
development or strategic acquisitions.
Over a long-term perspective, we
have a Neutral recommendation on Boston Scientific.
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Sep 2023 to Sep 2024